

ACI's Acclaimed Summit on Life Sciences IP Due Diligence is Returning to Boston November 9-10, 2020

Meet due diligence thought leaders from top Life Sciences companies that will help you develop strategies for the best results of the IP due diligence process.

NEW YORK, NY, USA, July 9, 2020 /EINPresswire.com/ -- ACI is excited to bring our 4th Annual Summit on Life Sciences [IP Due Diligence](#) back to Boston this November 9-10, 2020.



4th ANNUAL SUMMIT ON Life Sciences IP Due Diligence | November 9-10, 2020

Don't want to travel? Livestreaming the live event is available for you to attend without leaving home. Learn more here: <https://www.americanconference.com/life-sciences-ip-due-diligence/livestream/>



Hearing from professionals involved in due diligence on a daily basis was very informative."

Senior Intellectual Property Counsel

This is the only forum devoted to providing corporate and IP counsel with expert strategies for assessing, valuing and commercializing IP assets when conducting strategic due diligence on any deal.

Gain insights from Key Industry Stakeholders including:

- Akebia Therapeutics
- Akorn Pharmaceuticals
- Boehringer Ingelheim USA Corporation
- Cantel Medical
- Eisai Inc.
- Eli Lilly and Company
- Flagship Pioneering
- Genentech
- Gilead Sciences
- Merck

- Novartis Pharmaceuticals
- Omega Therapeutics
- Bieris Pharmaceuticals
- Roche
- Sanofi
- Takeda

Highlights for this year include sessions on:

- COVID-19's Impact on Biopharma Deal Making and Valuation of IP Assets
- Strategies for Performing a Robust Virtual/Remote IP Due Diligence Review
- Conducting IP Due Diligence in Connection with Distressed Assets
- Uncovering Red Flags in IP Ownership
- Assessing the Impact of Government Funding Initiatives on IP Rights and IP Evaluation
- Conducting IP Due Diligence on Deals Involving MedTech and AI
- How New Developments at FDA are Impacting the IP Due Diligence Review Process

[Complete agenda](#) is now available.

[Registration](#) is now open with early bird discounts. Don't miss this unique opportunity to learn from the Life Sciences industry due diligence thought leaders this November!

Linda Lam
 American Conference Institute
 +1 212-352-3220
[email us here](#)
 Visit us on social media:
[LinkedIn](#)

ACI American Conference Institute

EARN CLE/ETHICS CREDITS

4TH ANNUAL SUMMIT ON
Life Sciences
IP Due Diligence

A Life Sciences Industry Think Tank for Assessing, Valuing, and Commercializing IP Assets

November 9–10, 2020 | OMNI Parker House | Boston, MA
 Attend Virtually via Livestreaming

GAIN INSIGHTS FROM KEY INDUSTRY STAKEHOLDERS:

- Akbia Therapeutics
- Akorn Pharmaceuticals
- Boehringer Ingelheim USA Corporation
- Cantel Medical
- Eisai Inc.
- Eli Lilly and Company
- Flagship Pioneering
- Genentech
- Gilead Sciences
- Merck
- Novartis Pharmaceuticals
- Omega Therapeutics
- Pieris Pharmaceuticals
- Roche
- Sanofi
- Takeda

HIGHLIGHTS FOR THIS YEAR INCLUDE SESSIONS ON:

- > COVID-19's Impact on Biopharma Deal Making and Valuation of IP Assets
- > Strategies for Performing a Robust Virtual/Remote IP Due Diligence Review
- > Conducting IP Due Diligence in Connection with Distressed Assets
- > Uncovering Red Flags in IP Ownership
- > Assessing the Impact of Government Funding Initiatives on IP Rights and IP Evaluation
- > Conducting IP Due Diligence for MedTech and AI
- > How New Developments at FDA are Impacting the IP Due Diligence Review Process

Supporting Sponsor: **VENABLE | Fitzpatrick**

Media Partner: **Patent Docs**

A Fine Tune Your Due Diligence Strategies and Expertise by Attending our Conference Workshops:
 Life Sciences IP Due Diligence 101: Preparing Your Due Diligence Checklist and Managing the Process from Soup to Nuts

B Freedom to Operate Boot Camp: A Comprehensive Tactical Guide to Mastering the FTO Search

AmericanConference.com/IPDueDiligence • 888 224 2480

Part of ACI's LIFE SCIENCES GLOBAL SERIES

Download the conference brochure now:
<https://www.americanconference.com/life-sciences-ip-due-diligence/request-brochure/>

This press release can be viewed online at: <https://www.einpresswire.com/article/521312035>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.